Moderna aims to roll out a combined Covid-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm said, hoping a joint jab would encourage people to get an annual shot.
The single vaccine for Covid-19, influenza and respiratory syncytial virus — a common virus that causes the cold, but can be more serious for infants and elderly people — could appear on the market before 2024.
“Best-case scenario will be the fall of '23,” Moderna chief executive Stephane Bancel told a virtual World Economic Forum roundtable session.
“I don't think it would happen in every country, but we believe it's possible to happen in some countries next year."
